Hepatic arterial infusion chemotherapy: a review with technical notes

Abstract

Combined hepatic artery infusion (HAI) and systemic chemotherapy have demonstrated its clinical efficacy in prolonging overall survival in unresectable intrahepatic cholangiocarcinoma and as a conversion to treatment strategy in a small proportion of patients. The utilization of HAI chemotherapy is restricted by the scarcity of surgeons and oncologists who are well-experienced in its use. This represents a significant drawback of this treatment method. In recent years, a solid push to expand its use, mainly in the United States and recently also in Europe, has been made possible by the HAI Consortium Research Network. Results of ongoing Clinical Trials are eagerly awaited to give the basis for further expansion of this technique and oncological treatment outside of historically established centers. In this technical note review, we aim to give a brief historical description of the origins and evolution of intra-arterial chemotherapy for unresectable intrahepatic cholangiocarcinoma. We will, therefore, discuss the surgical technique by providing some tips and tricks without neglecting the difficulties that may be encountered.

Keywords

Hepatic artery infusion / pump chemotherapy / intrahepatic cholangiocarcinoma / unresectable cholangiocarcinoma / conversion therapy

References

[1] Ilyas SI.Pathogenesis, diagnosis, and management of cholangiocarcinoma.Gastroenterology2013;145:1215-29 PMCID:PMC3862291

[2] Banales JM,Carpino G.Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European network for the study of cholangiocarcinoma (ENS-CCA).Nat Rev Gastroenterol Hepatol2016;13:261-80

[3] Alvaro D,Benedetti A.AISF “Cholangiocarcinoma” committeeCholangiocarcinoma in Italy: a national survey on clinical characteristics, diagnostic modalities and treatment. results from the "cholangiocarcinoma" committee of the italian association for the study of liver disease.Dig Liver Dis2011;43:60-5

[4] Khan SA,Goldin RD.British Society of GastroenterologyGuidelines for the diagnosis and treatment of cholangiocarcinoma: an update.Gut2012;61:1657-69

[5] Banales JM,Lamarca A.Cholangiocarcinoma 2020: the next horizon in mechanisms and management.Nat Rev Gastroenterol Hepatol2020;17:557-88 PMCID:PMC7447603

[6] Rahib L,Matrisian LM.Estimated projection of US Cancer incidence and death to 2040.JAMA Netw Open2021;4:e214708 PMCID:PMC8027914

[7] Mosconi S,Labianca R,Gatta G.Cholangiocarcinoma.Crit Rev Oncol Hematol2009;69:259-70

[8] Cercek A,Tan BR.Assessment of hepatic arterial infusion of floxuridine in combination with systemic gemcitabine and oxaliplatin in patients with unresectable intrahepatic cholangiocarcinoma: a phase 2 clinical trial.JAMA Oncol2020;6:60-7 PMCID:PMC6824231

[9] Jarnagin WR,Gultekin DH.Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival.Ann Oncol2009;20:1589-95 PMCID:PMC2731015

[10] Kemeny NE,Gönen M.Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results?.Oncology2011;80:153-9 PMCID:PMC3123741

[11] Inaba Y,Yamaura H.Japan Interventional Radiology in Oncology Study Group (JIVROSG)Phase I/II study of hepatic arterial infusion chemotherapy with gemcitabine in patients with unresectable intrahepatic cholangiocarcinoma (JIVROSG-0301).Am J Clin Oncol2011;34:58-62

[12] Ghiringhelli F,Vincent J,Guiu B.Hepatic arterial infusion of gemcitabine plus oxaliplatin as second-line treatment for locally advanced intrahepatic cholangiocarcinoma: preliminary experience.Chemotherapy2013;59:354-60

[13] Massani M,Ruffolo C.Intrahepatic chemotherapy for unresectable cholangiocarcinoma: review of literature and personal experience.Updates Surg2015;67:389-400

[14] Konstantinidis IT,Do RK.Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone.Cancer2016;122:758-65 PMCID:PMC4764409

[15] Higaki T,Moriguchi M,Midorikawa Y.Arterial infusion of cisplatin plus S-1 against unresectable intrahepatic cholangiocarcinoma.Biosci Trends2018;12:73-8

[16] NCCN Guidelines Panel Members. Biliary Tract Cancers Version 2. Available from: https://www.nccn.org/professionals/physician_gls/pdf/btc.pdf [Last accessed on 11 May 2024]

[17] Klopp CT,Bateman J,Winship T.Fractionated intra-arterial cancer; chemotherapy with methyl bis amine hydrochloride; a preliminary report.Ann Surg1950;132:811-32 PMCID:PMC1616816

[18] Bierman HR,Miller ER.Effects of intra-arterial administration of nitrogen mustard.Am J Med1950;8:535

[19] Sullivan RD,Watkins E Jr.Chemotherapy of metastatic liver cancer by prolonged hepatic-artery infusion.N Engl J Med1964;270:321-7

[20] Narsete T,Wirtanen G,Wolberg W.Gastric ulceration in patients receiving intrahepatic infusion of 5-fluorouracil.Ann Surg1977;186:734-6 PMCID:PMC1396500

[21] Taylor I.Cytotoxic perfusion for colorectal liver metastases.Br J Surg1978;65:109-14

[22] Dahl EP,Tylén U.Transient hepatic dearterialization followed by regional intra-arterial 5-fluorouracil infusion as treatment for liver tumors.Ann Surg1981;193:82-8 PMCID:PMC1345007

[23] Patt YZ,Chuang VP.Percutaneous hepatic arterial infusion (HAI) of mitomycin C and floxuridine (FUDR): An effective treatment for metastatic colorectal carcinoma in the liver.Cancer1980;46:261-5

[24] Blackshear PJ,Blackshear PLJ,Buchwald H.A permanently implantable self-recycling low flow constant rate multipurpose infusion pump of simple design.Surg Forum1970;21:136-7.

[25] Blackshear PJ,Blackshear PLJ,Buchwald H.The design and initial testing of an implantable infusion pump.Surg Gynecol Obstet1972;134:51-6.

[26] Buchwald H,Vassilopoulos PP,Varco RL.Intraarterial infusion chemotherapy for hepatic carcinoma using a totally implantable infusion pump.Cancer1980;45:866-9

[27] Sigurdson ER,Kemeny N.Tumor and liver drug uptake following hepatic artery and portal vein infusion.J Clin Oncol1987;5:1836-40

[28] Ensminger WD.Clinical pharmacology of hepatic arterial chemotherapy.Semin Oncol1983;10:176-82.

[29] Johnson LP.The implanted pump in metastatic colorectal cancer of the liver. Risk versus benefit.Am J Surg1985;149:595-8

[30] Weiss GR,Osteen RT.Long-term hepatic arterial infusion of 5-fluorodeoxyuridine for liver metastases using an implantable infusion pump.J Clin Oncol1983;1:337-44

[31] Thiels CA.Hepatic artery infusion pumps.J Surg Oncol2020;122:70-7 PMCID:PMC9014308

[32] Kemeny N,Reichman B,Botet J.Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial.Ann Intern Med1987;107:459-65

[33] Datta J,Kemeny NE.Role of hepatic artery infusion chemotherapy in treatment of initially unresectable colorectal liver metastases: a review.JAMA Surg2019;154:768-76

[34] Kemeny NE.Hepatic arterial infusion after liver resection.N Engl J Med2005;352:734-5

[35] Kemeny N.Hepatic-arterial chemotherapy.Lancet Oncol2001;2:418-28

[36] Allen PJ,Ben-Porat L.The management of variant arterial anatomy during hepatic arterial infusion pump placement.Ann Surg Oncol2002;9:875-80

[37] Allen PJ,Picon AI.Technical complications and durability of hepatic artery infusion pumps for unresectable colorectal liver metastases: an institutional experience of 544 consecutive cases.J Am Coll Surg2005;201:57-65

[38] Redman HC.Arterial collaterals in the liver hilus.Radiology1970;94:575-9

[39] Koehler RE,Lewis F.Arteriographic demonstration of collateral arterial supply to the liver after hepatic artery ligation.Radiology1975;117:49-54

[40] Rayner AA,Stagg RJ,Hohn DC.Total hepatic arterial perfusion after occlusion of variant lobar vessels: implications for hepatic arterial chemotherapy.Surgery1986;99:708-15.

[41] Cohen AM,Waltman AC,McKusick K.Effect of ligation of variant hepatic arterial structures on the completeness of regional chemotherapy infusion.Am J Surg1987;153:378-80

[42] Curley SA,Roh MS.Technical considerations and complications associated with the placement of 180 implantable hepatic arterial infusion devices.Surgery1993;114:928-35.

[43] Rougier P,Huguier M.Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial.J Clin Oncol1992;10:1112-8

[44] Aziz H.We asked the experts: role of lymphadenectomy in surgical management of intrahepatic cholangiocarcinoma.World J Surg2023;47:1530-2

[45] Bartsch F,Müller L.Relevance of suspicious lymph nodes in preoperative imaging for resectability, recurrence and survival of intrahepatic cholangiocarcinoma.BMC Surg2020;20:75 PMCID:PMC7161232

[46] Zhou R,Li W.Is lymph node dissection necessary for resectable intrahepatic cholangiocarcinoma? A systematic review and meta-analysi.HPB (Oxford)2019;21:784-92

[47] Weber SM,O'Reilly EM,Miyazaki M.Intrahepatic cholangiocarcinoma: expert consensus statement.HPB (Oxford)2015;17:669-80 PMCID:PMC4527852

[48] Daly JM,Oderman P.Long-term hepatic arterial infusion chemotherapy. Anatomic considerations, operative technique, and treatment morbidity.Arch Surg1984;119:936-41

[49] Heinrich S,Schwinnen I.Technical complications of continuous intra-arterial chemotherapy with 5-fluorodeoxyuridine and 5-fluorouracil for colorectal liver metastases.Surgery2003;133:40-8

[50] Creasy JM,Reed SA.Implementation of a hepatic artery infusion program: initial patient selection and perioperative outcomes of concurrent hepatic artery infusion and systemic chemotherapy for colorectal liver metastases.Ann Surg Oncol2020;27:5086-95

[51] Janczewski LM,Lidsky ME,Merkow RP.Hepatic artery infusion chemotherapy: a quality framework.Ann Surg Oncol2024;31:701-4

[52] Sharib JM,Wildman-Tobriner B.Hepatic artery infusion pumps: a surgical toolkit for intraoperative decision-making and management of hepatic artery infusion-specific complications.Ann Surg2022;276:943-56 PMCID:PMC9700364

[53] Kerr DJ,Ledermann J.Medical Research Council's colorectal cancer study groupEuropean Organisation for Research and Treatment of Cancer colorectal cancer study groupIntrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial.Lancet2003;361:368-73

[54] Ito K,Kemeny NE.Biliary sclerosis after hepatic arterial infusion pump chemotherapy for patients with colorectal cancer liver metastasis: incidence, clinical features, and risk factors.Ann Surg Oncol2012;19:1609-17

[55] Kemeny MM,Blayney DW.Sclerosing cholangitis after continuous hepatic artery infusion of FUDR.Ann Surg1985;202:176-81 PMCID:PMC1250871

[56] Kemeny N,Niedzwiecki D.A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dexamethasoneversus fluorodeoxyuridine alone in the treatment of metastatic colorectal cancer.Cancer1992;69:327-34

[57] Kemeny NE,Hollis DR.Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481).J Clin Oncol2006;24:1395-403

[58] Chang AE,Sugarbaker PH,Culnane M.A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases.Ann Surg1987;206:685-93 PMCID:PMC1493315

[59] Hohn DC,Friedman MA.A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California oncology group trial.J Clin Oncol1989;7:1646-54

[60] Martin JK Jr,Wieand HS.Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial.Arch Surg1990;125:1022-7

[61] Lorenz M.Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma.J Clin Oncol2000;18:243-54

[62] Kemeny MM,Gray B.Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy--an intergroup study.J Clin Oncol2002;20:1499-505

[63] Martin RC,McMasters KM.Morbidity of adjuvant hepatic arterial infusion pump chemotherapy in the management of colorectal cancer metastatic to the liver.Am J Surg2004;188:714-21